Frost MC, Zhang L, Kim HM, Lin LA. Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Netw Open. 2022;5(10):e2236298. doi:10.1001/jamanetworkopen.2022.36298

**eTable 1.** Definitions of Measures Using Diagnostic Codes and/or Clinic Visit Codes

**eTable 2.** Association Between Treatment Modality and 90-Day Retention Among VHA Patients Who Received Buprenorphine for OUD in the Year Following COVID-19-Related Changes

This supplemental material has been provided by the authors to give readers additional information about their work.
**eTable 1. Definitions of measures using diagnostic codes and/or clinic visit codes**

| Measure                                                                 | Definition                                                                 |
|--------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Opioid use disorder                                                      | ICD-10-CM codes: F11*                                                     |
| Video telehealth modality                                               | Clinic visit codes (secondary): 690, 692, 693, 699, 644, 645, 136, 137, 444, 445, 446, 447, 440, 708, 723, 724, 490, 491, 179, 679, 648 Or with CPT modifier = GT/95 |
| Telephone telehealth modality                                           | CPT codes: 99441, 99442, 99443 or Clinic visits codes (primary): 545, 527, 338 (or other codes with "phone" in the name which including: 103, 147, 148, 169, 178, 181, 182, 199, 216, 221, 229, 324, 325, 326, 424, 425, 428, 441, 451, 452, 453, 454, 462, 463, 476, 526, 527, 528, 530, 536, 537, 542, 543, 544, 545, 546, 579, 584, 597, 609, 611, 686, 729, 801, 802, 803) |
| Homelessness and/or housing instability                                 | ICD-10-CM codes: Z59.0, Z59.1, Z59.3, Z59.8, Z59.9 Clinic visit codes: 504, 507, 508, 511, 522, 528, 529, 530, 555, 556, 590, 76, 453, 455, 458, 460, 501 |
| Alcohol use disorder                                                   | ICD-10-CM codes: F10*                                                    |
| Stimulant use disorder                                                  | ICD-10-CM codes: F14*, F15*                                              |
| Cannabis use disorder                                                  | ICD-10-CM codes: F12*                                                    |
| Other drug use disorder (sedative, hallucinogen, inhalant and/or other psychoactive substance) | ICD-10-CM codes: F13*, F16*, F18*, F19*                                  |
| Depressive disorder                                                    | ICD-10-CM codes: F32*, F33*                                              |
| Post-traumatic stress disorder                                         | ICD-10-CM codes: F43.1*                                                  |
| Other anxiety disorder                                                 | ICD-10-CM codes: F06.4, F40*, F41*, F42*, F43*, F45.2*, R45.7            |
| Serious mental illness (bipolar disorder, psychosis and/or schizophrenia) | ICD-10-CM codes: F20*, F25*, F22, F23, F24, F28, F29, F53.1, F06.0, F06.2, F06.3*, F30*, F31* |

* Indicates inclusion of all sub-codes under parent code.
### eTable 2. Association between treatment modality and 90-day retention among VHA patients who received buprenorphine for OUD in the year following COVID-19-related changes

|                          | All patients (N=17,182) | Patients with any telehealth visits (N=15,071) |
|--------------------------|-------------------------|-----------------------------------------------|
|                          | aOR\(^a\) for retained ≥90 days (predictor: any telehealth vs. in-person only) | 95% CI | aOR\(^a\) for retained ≥90 days (predictor: any video vs. telephone only) | 95% CI |
| Initiated in year following COVID (N=4,338 among all patients) | 1.31 | (1.12, 1.53) | 1.47 | (1.26, 1.71) |
| Initiated prior to COVID (N=12,844 among all patients) | 1.23 | (1.08, 1.39) | 1.06 | (0.98, 1.13) |

\(^a\)Adjusted for age, sex, race, ethnicity, VHA eligibility status, rurality of patient residence, homelessness and/or housing instability, alcohol use disorder, cannabis use disorder, stimulant use disorder, other drug use disorder (sedative, hallucinogen, inhalant and/or other psychoactive substance), depressive disorder, post-traumatic stress disorder, other anxiety disorder, serious mental illness (bipolar disorder, psychosis and/or schizophrenia), and number of Elixhauser comorbidities (excluding OUD).